Publications by authors named "Brenda Chyla"

28Publications

Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.

Clin Pharmacol Ther 2020 Aug 4. Epub 2020 Aug 4.

Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.2005DOI Listing
August 2020

Response in patients with -mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab.

Haematologica 2020 Jul;105(7):e382-e383

Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2020.253849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327665PMC
July 2020

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

J Clin Oncol 2018 07 1;36(19):1973-1980. Epub 2018 May 1.

Stephan Stilgenbauer and Johannes Bloehdorn, Ulm University, Ulm; Stephan Stilgenbauer, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; Barbara Eichhorst and Michael Hallek, Universitätsklinikum Köln, Köln; Johannes Schetelig, University Hospital, Technische Universität Dresden, Dresden; Clemens-Martin Wendtner, Klinikum Schwabing, Munich; Sebastian Böttcher, University Hospital of Schleswig-Holstein, Kiel, Germany; Peter Hillmen and Talha Munir, St James's University Hospital, Leeds; Anna Schuh, University of Oxford; Anna Schuh, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; John F. Seymour, Peter MacCallum Cancer Centre; John F. Seymour, University of Melbourne; Andrew W. Roberts, Royal Melbourne Hospital, Parkville, Victoria; Stephen P. Mulligan, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Steven Coutre, Stanford University Medical Center, Stanford, CA; Wojciech Jurczak, Jagiellonian University, Kraków, Poland; Sarit Assouline, McGill University, Montreal, Quebec, Canada; Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer Arzt, Su Young Kim, Maria Verdugo, and Gary Gordon, AbbVie, North Chicago, IL; Ahmed Hamed Salem, Ain Shams University, Cairo, Egypt; and William G. Wierda, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6840DOI Listing
July 2018

Development of a flow cytometric method for quantification of BCL-2 family members in chronic lymphocytic leukemia and correlation with sensitivity to BCL-2 family inhibitors.

Cytometry B Clin Cytom 2017 09 4;92(5):331-339. Epub 2016 Jul 4.

Research and Development, Oncology Discovery, AbbVie, Inc, 1 North Waukegan Rd, North Chicago, Illinois, 60064.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21383DOI Listing
September 2017

A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.

Neuro Oncol 2014 Dec 7;16(12):1661-8. Epub 2014 Jun 7.

Texas Children's Cancer Center, Baylor College of Medicine (J.M.S., P.T., A.A., X-N.L., S.M.B.); Children's National Medical Center (L.K.); St. Jude Children's Research Hospital (A.O-T., J.B., L.K.); University of Tennessee Health Science Center (M.K.); AbbVie Pharmaceuticals (B.C., E.M., V.G.); National Cancer Institute, Pediatric Oncology Branch (K.E.W.); Children's Hospital of Chicago (S.G.); Children's Hospital of Pittsburgh (I.F.P.); Cincinnati Children's Hospital Medical Center (M.F.); Cancer Therapy Evaluation Program, National Cancer Institute (A.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232081PMC
December 2014

Biomarkers of therapeutic response to BCL2 antagonists in cancer.

Mol Diagn Ther 2012 Dec;16(6):347-56

Department R4CD, Global Pharmaceutical R&D, Abbott Laboratories, Building AP-10, 100 Abbott Park Road, Abbott Park, IL 60064, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40291-012-0003-6DOI Listing
December 2012

Myeloid translocation gene 16 is required for maintenance of haematopoietic stem cell quiescence.

EMBO J 2012 Mar 20;31(6):1494-505. Epub 2012 Jan 20.

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://emboj.embopress.org/cgi/doi/10.1038/emboj.2011.500
Publisher Site
http://dx.doi.org/10.1038/emboj.2011.500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321173PMC
March 2012

Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation.

Mol Cell Biol 2008 Oct 18;28(20):6234-47. Epub 2008 Aug 18.

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.00404-08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577421PMC
October 2008

Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks.

EMBO J 2008 Apr 20;27(7):1017-28. Epub 2008 Mar 20.

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/emboj.2008.51DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2323257PMC
April 2008

Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis.

Blood 2008 Apr 23;111(7):3760-9. Epub 2008 Jan 23.

BloodCenter of Wisconsin, Blood Research Institute, Milwaukee 53226, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2007-08-108803DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275032PMC
April 2008